Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613715 | 0.84 | MEN1 (0.34) | LTB4RMEN1KMT2A | |
| SCHEMBL4501127 | 0.71 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL4512133 | 0.69 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL4501241 | 0.69 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL18723624 | 0.69 | LTB4R (0.43) | LTB4R | |
| SCHEMBL4511710 | 0.69 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL30669416 | 0.68 | LTB4R (0.44) | LTB4RMEN1KMT2A | |
| SCHEMBL4584887 | 0.67 | SLC6A3 (0.37) | LTB4RKMT2A | |
| SCHEMBL20764816 | 0.67 | CA2 (0.34) | LTB4R | |
| SCHEMBL5481203 | 0.67 | ALDH1A1 (0.49) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | LTB4R 95/4885MEN1 4619/4885KMT2A 4609/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | LTB4R 95/4885MEN1 4619/4885KMT2A 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.